|
|
 |
Your Online Resource for Diabetes Treatment
Home > Literature
Alerts > Archived
by Journal > American Heart Journal
American Heart Journal | 
|
| • |
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction
Goyal A, Mehta SR, Gerstein HC, et al
Am Heart J. 2009;157(4):763-770 |
| • |
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction
Goyal A, Mehta SR, Gerstein HC, et al
Am Heart J. 2009;157(4):763-770 |
| • |
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics
Ratner RE, Cannon CP, Gerstein HC, et al; for the APPROACH Study Group
Am Heart J. Am Heart J. 2008;156(6):1074-1079 |
| • |
Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial
Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group
Am Heart J. 2008;156(3):528-536 |
| • |
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group
Am Heart J. 2008;156(4):623-632 |
| • |
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators.
Am Heart J. 2008 Apr;155(4):712-7. Epub 2008 Feb 21. |
| • |
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
Origin Trial Investigators , Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J.
Am Heart J. 155(1):26-32, 32.e1-6 |
| • |
Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: a randomized crossover trial.
Ribeiro LW, Ribeiro JP, Stein R, Leitão C, Polanczyk CA
Am Heart J. 2007 Jul; 154(1): 78.e1-7 |
| • |
Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial
Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL
Am Heart J. 2004;148:883-888 |
| • |
Approach to the management of diabetic patients with heart failure: role of thiazolidinediones
Fonarow GC
Am Heart J. 2004;148:551-558 |
| • |
The Diabetic Postoperative Mortality and Morbidity (DIPOM) trial: rationale and design of a multicenter, randomized, placebo-controlled, clinical trial of metoprolol for patients with diabetes mellitus who are undergoing major noncardiac surgery
Juul AB, Wetterslev J, Kofoed-Enevoldsen A, Callesen T, Jensen G, Gluud C
Am Heart J. 2004;147:677-683 |
| • |
Pioglitazone Reduces Neointimal Tissue Proliferation After Coronary Atent Implantation in Patients With Type 2 Diabetes Mellitus: An Intravascular Uultrasound Scanning Study
Takagi T, Yamamuro A, Tamita K, et al
Am Heart J. 2003;146:E5 |
| • |
Impaired Glucose Levels Are a Predictor of Mortality in Nondiabetic Patients With Ischemic Heart Disease, Study Finds
|
|
